APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 7667, the Food and Drug Amendments of 2022, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; S 4348, Food and Drug Safety and Landmark Advancement Act, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; Senator Tina Smith Amendment #1 to S 4348, provisions relating to amending the Hatch-Waxman 180 exclusivity structure to prevent market blockages; HR 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act 180-day exclusivity structure; and S2910, Expanding Access to Low Cost Generics Act, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.